On April 7, 2021 Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIOP), reported it will be presenting a poster at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual 2021 Annual Meeting (Press release, Ziopharm, APR 7, 2021, View Source [SID1234577667]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster highlights work evaluating the ability of the non-viral Sleeping Beauty transposon/transposase gene transfer system to re-direct the specificity of T cells towards p53 and KRAS neoantigens and characterizing the resultant engineered TCR-T cell populations for specificity and function.
The poster is entitled "Hotspot mutations in KRAS and TP53 targeted by TCR-T cells genetically modified with the Sleeping Beauty transposon/transposase system."
The work summarized in the poster demonstrates that multiple TCRs with unique specificities targeting recurrent p53 and KRAS substitutions in frequent HLA haplotypes could be stably expressed using Sleeping Beauty transposition to re-direct peripheral blood T cells towards tumor cells.
Dr. Raffaele Baffa, MD, PhD, Chief Medical Officer of Ziopharm said, "We are pleased to share this update on our TCR-T directed work with the scientific community. The Company is working tirelessly on our Phase I/II clinical study for our TCR-T Library, and the work presented in this poster provides us with increased confidence in the scientific rationale behind the trial."
The poster will be presented as part of Session PO.IM02.01 – Adoptive Cell Therapy. The abstract for the poster can be found on the AACR (Free AACR Whitepaper) website using this link. The poster will be available for conference participants beginning at 8:30am ET on Saturday, April 10, 2021 and will also be posted on the Ziopharm Oncology website in the Investors section, using this link.